Ex. Subsequent Offering Today

Core Viewpoint - Hofseth Biocare ASA ("HBC" or "the Company") is planning a subsequent offering of up to 16,666,666 new shares directed towards certain eligible shareholders, with trading of shares commencing exclusive of the right to participate in this offering from October 27, 2025 [2]. Group 1 - The subsequent offering is contingent upon resolution and execution, indicating that the shares will be traded without the right to participate in the offering from the specified date [2]. - The legal advisor for the Company in this matter is Advokatfirmaet CLP DA [3]. - The announcement does not constitute an offer to sell or a solicitation to purchase any securities of the Company [3][10]. Group 2 - The communication is directed only at qualified investors in the EEA Member States and is compliant with the Prospectus Regulation [5]. - In the United Kingdom, the communication is aimed at investment professionals and high net worth entities, ensuring that it is only acted upon by relevant persons [6]. - The Company does not intend to register any part of the offering in the United States, and any sales will be made solely to "qualified institutional buyers" as defined under U.S. securities laws [4]. Group 3 - The announcement includes forward-looking statements that are subject to various risks and uncertainties, which may cause actual events to differ from expectations [9]. - The Company does not guarantee the accuracy of the assumptions underlying any forward-looking statements and has no obligation to update or revise these statements [9]. - The distribution of this announcement may be restricted by law in certain jurisdictions, and recipients are advised to inform themselves about and observe any such restrictions [8][10].